“…HMGB1 also forms various complexes with many different molecules in the extracellular milieu, promoting additional pro-inflammatory activities through interaction with TLR2, TLR3, TLR9, and the IL-1 receptor (Bianchi, 2009;Janko et al, 2013). HMGB1 plays significant roles in the pathophysiology of sterile inflammation (Andersson and Tracey, 2011) associated with diverse acute and chronic conditions, including myocardial infarction (Loukili et al, 2011), hepatic ischemia (Tsung et al, 2005), stroke (Schulze et al, 2013), circulatory shock and trauma (Andersson and Tracey, 2011), diabetes (Nogueira-Machado et al, 2011), cancer (Krysko et al, 2012), and arthritis (Harris et al, 2012), and it also acts as a key pro-inflammatory cytokine involved in the pathogenesis of sepsis (Yang et al, 2004). Thus, HMGB1 emerges as a central acting mediator at the intersection between sterile and infectious inflammation (Andersson and Tracey, 2011).…”